Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals reported financial results for Q2 2021, achieving significant clinical milestones in its NASH pipeline. The company initiated the Phase 1b AVIATION Trial for TERN-201 and completed a multiple ascending dose portion of the TERN-501 trial. Cash reserves are strong at $185.1 million, projected to last until 2024. Top-line data from TERN-501 is expected in 4Q 2021 and from TERN-201 in 1H 2022. Despite a net loss of $10.7 million for the quarter, decreased R&D expenses show a positive trend for operating efficiency.

Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced its participation in two key healthcare conferences. Management will join a liver disease panel at the 2021 Wedbush PacGrow Healthcare Conference on August 10 at 2:20 PM ET. Additionally, Terns will present at the Canaccord Genuity 41st Annual Growth Conference on August 11 at 1:00 PM ET. Both events will be available via live webcast on Terns' investor relations page, with replays accessible for 30 days post-presentation.

Terns Pharmaceuticals initiated patient dosing for the AVIATION Trial, a Phase 1b study evaluating TERN-201, a selective VAP-1 inhibitor targeting chronic liver inflammation and fibrosis in NASH. This trial aims to assess the safety and efficacy of TERN-201 over a 12-week period, with preliminary data expected in 2022. TERN-201 demonstrated well-tolerated results in prior studies, showing significant potential in reducing liver inflammation. The drug's selective inhibition may complement other therapies in Terns’ portfolio.

Terns Pharmaceuticals reported positive results from the Phase 2a LIFT clinical trial of TERN-101, an FXR agonist for NASH treatment. The trial demonstrated no discontinuations due to adverse events, including pruritus, and significant improvements in corrected T1 (cT1), a liver inflammation and fibrosis marker. After 12 weeks, significant changes in cT1 were observed in the 10 mg and 15 mg groups compared to placebo. Terns plans a combination trial of TERN-101 with TERN-501 in early 2022, following these promising outcomes.

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced a conference call to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with non-alcoholic steatohepatitis (NASH). The call is scheduled for June 14, 2021, at 8:30 a.m. ET, with a live webcast available. Terns focuses on developing small-molecule therapies targeting NASH and chronic liver diseases, aiming to offer significant clinical benefits based on validated mechanisms of action. The details of the webcast and conference call are provided for interested stakeholders.

Terns Pharmaceuticals is set to present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 12:00 p.m. ET, followed by participation in the J.P. Morgan Biotech 2021 CEO Conference Call Series on May 25, 2021, at 1:00 p.m. ET. A live audio webcast will be accessible on the company’s investor page, with a 30-day archive available post-event. Terns specializes in developing small-molecule therapy candidates for non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. For more details, visit their official website.

Terns Pharmaceuticals reported Q1 2021 financial results and corporate updates, highlighting advancements in their NASH clinical programs. With top-line data for the Phase 2a LIFT study of TERN-101 expected in June 2021, the company emphasizes the focus on safety and multiple non-invasive endpoints. The oversubscribed IPO raised $147 million, enhancing their financial position. R&D expenses rose to $8.7 million, while the net loss increased to $13.3 million from $9.2 million a year earlier. Cash reserves of $195.6 million are projected to support operations through 2024.

On April 7, 2021, Terns Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced its participation in the 19th Annual Virtual Needham Healthcare Conference. The presentation is set for April 14 at 11:40 a.m. ET. Interested parties can access a live audio webcast through the conference and Terns’ website, with a replay available for 30 days post-event. Terns focuses on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases, utilizing clinically validated mechanisms to benefit patients.

Terns Pharmaceuticals reported a strong financial position with $75 million in cash as of Q4 2020, following an upsized IPO that raised approximately $147 million in February 2021. The company is advancing its pipeline for treating non-alcoholic steatohepatitis (NASH) with three clinical-stage candidates: TERN-101 (Phase 2a), TERN-201 (Phase 1), and TERN-501 (Phase 1). Key milestones include expected data readouts in mid-2021. The company reduced total net loss to $40.6 million from $68.8 million in 2019, indicating improved cost management.